Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Idarucizumab Humanized Recombinant Human Monoclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Idarucizumab Humanized Antibody (MA5-41998) in SDS-PAGE
SDS-PAGE analysis of the recombinant Pradaxa (Dabigatran Etexilate Mesylate) dabigatran etexilate mesylate protein expressed in CHO cells using a Idarucizumab biosimilar monoclonal antibody (Product # MA5-41998). R denotes the lane was run under reducing conditions. NR denotes the lane was run under non-reducing conditions.
产品信息
MA5-41998
产品规格
种属反应
Chemical
宿主/亚型
Human
/ IgG1, F(ab), kappa
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
抗原
Pradaxa (Dabigatran Etexilate Mesylate) dabigatran etexilate mesylate
偶联物
形式
Liquid
浓度
2.53 mg/mL
纯化类型
Protein A/G
保存液
30mM histidine/PBS, pH 6.0, with 10% sucrose, 60ppm Tween 80
内含物
no preservative
保存条件
-20°C, Avoid Freeze/Thaw Cycles
运输条件
Ambient (domestic); Wet ice (international)
RRID
产品详细信息
Endotoxin level < 0.01EU/µg by LAL method
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
靶标信息
Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its anticoagulant effect. As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, especially when given to patients at increased risk (elderly, chronic kidney disease, concomitant NSAID or warfarin use, etc.). Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations. Its use is associated with immediate, complete and sustained reversal of the anticoagulant effects of dabigatran. Idarucizumab protein structure can be viewed below, with disulfide bridges at the following points: H22-H95, H149-H205, H225-L-219, L23-L93, L139-L199.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
